Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

SUTRO BIOPHARMA, INC. (STRO) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

SUTRO BIOPHARMA, INC. (STRO), most recent 12 months reported: revenue $45.7M, net loss $180.64M. Latest balance sheet on file: liquid cash $164.35M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Recursion Pharmaceuticals, Inc. · Coherus Oncology, Inc. · BioStem Technologies, Inc. · EDITAS MEDICINE, INC. · PRECISION BIOSCIENCES INC · Pelthos Therapeutics Inc. · C4 Therapeutics, Inc. · SANGAMO THERAPEUTICS, INC.

Stock screener

Watchlist